PhaseV
PhaseV is an Israeli-founded clinical AI startup that applies machine learning and Bayesian optimization to improve trial design, execution efficiency, and outcome probability.
Visit WebsiteCompany Overview
PhaseV focuses on clinical development optimization, where trial cost, duration, and enrollment inefficiencies can delay therapeutic innovation. The platform uses AI/ML to improve protocol design, patient stratification, and operational decisions across trial lifecycles.
The company operates in a high-value biopharma analytics market where measurable impact on trial success and timeline compression drives adoption. Differentiation depends on model quality, regulatory usability, and integration with sponsor/CRO workflows.
Dual-use relevance is moderate but meaningful: advanced clinical optimization methods can support public health preparedness and regulated biomedical programs where speed and accuracy are critical.
Dual-Use Assessment
Clinical trial optimization AI is dual-use capability for commercial biopharma and regulated public-sector biomedical programs.
Key Technologies
- AI/ML optimization for clinical trial design
- Bayesian and adaptive trial analytics workflows
- Patient stratification and heterogeneity analysis
- Operational forecasting for enrollment and site performance
- Decision-support tooling for sponsor and CRO execution
Use Cases & Applications
- Reducing trial timelines and enrollment overhead
- Improving probability of clinical trial success
- Optimizing protocol design using historical and live trial data
- Enhancing CRO/sponsor decision quality during study execution
- Supporting high-assurance biomedical programs with data-driven trial planning
Strategic Value to U.S.-Israel Alliance
Can improve biomedical innovation throughput and evidence-driven decisioning in allied healthcare and preparedness ecosystems.
Interested in this startup?
Learn more about our investment approach or get in touch to discuss opportunities in dual-use technology.